Company / Working Capital
Pacira BioSciences, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$427.4M
FY2025
5-year range
$344.9M / $435.2M
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#102 of 213
Health Care
What the data says
At $427M, Pacira BioSciences, Inc.'s working capital ranks #102 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $198M in FY2016 to $435M in FY2024.
Based on SEC 10-K filings.
$427M in FY2025 with a 5-year CAGR of +1.4%.
Improved from $413M to $427M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +6.8%
- 5-Year CAGR
- +1.4%
- 10-Year CAGR
- -
Sector benchmark
#102 of 213 in Health CareTop 48% of 213This company $427.4M Sector average $934.6M
▼
-54.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.4%, indicating consistent growth.
- In FY2025, working capital decreased 1.8% year-over-year.
- Ranks #102 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $427.4M | -1.8% |
| FY2024 | $435.2M | +5.5% |
| FY2023 | $412.6M | +17.7% |
| FY2022 | $350.6M | +1.6% |
| FY2021 | $344.9M | -13.4% |
| FY2020 | $398.3M | +32.4% |
| FY2019 | $300.9M | -27.9% |
| FY2018 | $417.3M | +24.6% |
| FY2017 | $334.9M | +68.9% |
| FY2016 | $198.3M | +92.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026